Literature DB >> 21726178

Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors.

Sophie Roca, Amandine Quivy, Marine Gross-Goupil, Jean-Christophe Bernhard, Henri De Clermont, Alain Ravaud.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21726178     DOI： 10.3109/0284186X.2011.592149

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  4 in total

1.  Expression of phosphorylated mTOR and its regulatory protein is related to biological behaviors of ameloblastoma.

Authors:  Ning Li; Ming Zhong; Ming Song
Journal:  Int J Clin Exp Pathol       Date:  2012-09-05

2.  Expression of phosphorylated Akt/mTOR and clinical significance in human ameloblastoma.

Authors:  Ning Li; Jianfu Sui; Hao Liu; Ming Zhong; Min Zhang; Yan Wang; Fengyu Hao
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 3.  The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma.

Authors:  Julio Lambea; Urbano Anido; Olatz Etxániz; Luis Flores; Álvaro Montesa; Juan Manuel Sepúlveda; Emilio Esteban
Journal:  Curr Oncol Rep       Date:  2016-11       Impact factor: 5.075

4.  Metastatic renal cell carcinoma change vascularity.

Authors:  Takeshi Azuma; Yukihide Matayoshi; Yohsuke Sato; Yujiro Sato; Yasushi Nagase
Journal:  Case Rep Urol       Date:  2012-08-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.